trial summary · NCT07903623
QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia
A Prospective, Single-Arm, Single-Center Clinical Study of QLS4131 Combined With Isatuximab in Patients With Newly Diagnosed Primary Plasma Cell Leukemia
Trial record from the TrialBase DB dataset, status RECRUITING, condition Primary Plasma Cell Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The goal of this clinical trial is to learn whether QLS4131, a BCMA/GPRC5D/CD3 trispecific antibody, can improve treatment outcomes when combined with isatuximab in adults with newly diagnosed primary plasma cell leukemia (pPCL). The study will also evaluate the safety of this treatment combination. The main questions it aims to answer are: * How many participants achieve measurable residual disease (MRD) negativity after 9 treatment cycles? * What side effects occur during treatment with QLS4131 combined with isatuximab? * How many participants respond to treatment, and how many achieve a complete response? * How many participants achieve sustained MRD negativity? * How long do participants remain free from disease progression, and how long do they survive after starting treatment? All participants will receive the study treatment. There is no comparison group in this study. Participants will: * Receive QLS4131 by subcutaneous injection together with intravenous isatuximab in 28-day treatment cycles. * Undergo regular blood tests, bone marrow examinations, and disease assessments to monitor treatment response and safety. * Undergo peripheral blood stem cell mobilization and collection after the first 3 treatment cycles, if appropriate. * Be monitored throughout the study for side effects, including adverse events and serious adverse events.
Source record: https://clinicaltrials.gov/study/NCT07903623
Facts
| registry id | NCT07903623 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Primary Plasma Cell Leukemia |
| sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| sponsor class | OTHER |
| enrollment | 15 |
| start date | 2026-10-25 |
| primary completion | 2029-12-30 |
| completion | 2031-12-30 |
| results posted | not reported |
Conditions
- Primary Plasma Cell Leukemia
Interventions
- QLS4131
- Isatuximab
Countries
- China
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.